DeutschNewstral
Article
jdsupra.com on 2020-04-04 23:40
Special Master Appointed to Decide Requests to Seal and Redact in Genentech v. Amgen BPCIA Litigations
Related news
- New BPCIA Complaint: Genentech Sues Amgen over Proposed Trastuzumab Biosimilarjdsupra.com
- BPCIA Helps Amgen Gain Dismissal of Genentech Complaintjdsupra.com
- Genentech v. Amgen Jury Trial Postponedjdsupra.com
- New BPCIA Complaint: Amgen Sues Pfizer over Proposed Filgrastim Biosimilarjdsupra.com
- Biosimilar Appellate Update: Genentech v. Immunex, Genentech v. Amgen, Janssen v. Celltrionjdsupra.com
- Genentech Requests Expedited Resolution of Patent Dance Dispute Against Amgenjdsupra.com
- New BPCIA Complaint: Genentech Sues Samsung Bioepis Regarding Proposed Trastuzumab Biosimilarjdsupra.com
- District Court of Delaware Construes “Following Fermentation” in Genentech v. Amgen Trastuzumab and Bevacizumab Casesjdsupra.com
- Genentech BPCIA Trastuzumab Case Against Tanvez Dismissed After Settlementjdsupra.com
- Amgen and Sandoz Settle Denosumab BPCIA Litigationjdsupra.com
- When Redactions Don’t Redactjdsupra.com
- PGenentech sues Amgen over biosimilar drug infopacbiztimes.com
- Delaware District Court Dismisses Genentech v. Amgenjdsupra.com
- Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumabjdsupra.com
- Genentech Seeks “Urgent” Relief from Amgen’s Alleged BPCIA Violationsjdsupra.com
- Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigationjdsupra.com
- Amgen v. Sandoz BPCIA Dispute Heads to the Federal Circuitjdsupra.com
- Amgen Files BPCIA Complaint Against Sandoz Regarding Denosumabjdsupra.com
- Amgen Files BPCIA Complaint Against Samsung Bioepsis Regarding Denosumabjdsupra.com
- Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumabjdsupra.com